hotspot -WSS

hotspot

author：comprehensive 2025-10-01 21:40:45 - browse：25626

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Does good food count as health care? Study aims to find out

WSS

Woman gored by Bison at Yellowstone

Ransomware attacks on hospitals: Study outlines patient impact

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Federal judge rules Oregon’s tough new gun law is constitutional

Who gets to use the title 'doctor'?

Involuntary treatment for addiction doesn't work

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Sports medicine is finally prioritizing gender equality

Morphosys mixed study results for blood cancer drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Anesthesiologist group: stop taking Ozempic before surgery

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Activists slam private health insurers over coverage restrictions

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Medicare details structure of new drug price negotiation program

David Sabatini, ex

hotspot

Blood tests recalled over risk of missed heart attack diagnosis

Why police arrested suspected Gilgo Beach killer away from his house

Georgia court denies Trump's request to quash DA's 2020 election probe

Anthos stroke drug appears safer than common blood thinner

Morphosys mixed study results for blood cancer drug

FDA's Woodcock to retire early next year

hotspot

Wikipedia

knowledge

Wikipedia